Ann: Update - Proposed issue of securities - ANP, page-56

I don't think anyone is selling in order to render the SPP a failure. If a big seller is getting out it would be purely an investment decision on their part, selling to sabotage a SPP wouldn't work to anyone's advantage. I think the heavy selling we are seeing (at a 25% discount to the SPP and now approaching a 50% discount to last month's price) is an indication that investors, myself included, are tired of Diamond's empty rhetoric. If you talk about NON-DILUTIVE funding options with shareholders for the better part of a year, and then go ahead and do what he just did, it shows a complete failure on his part to follow through on this and negotiate a good funding/partnership deal with the 'inbound big pharma interest' he loved to talk about. A complete failure, especially when you consider how strong ATL1102's clinical data is...